key: cord-0755885-c8c6xa05
authors: Ahmed, Syed Hassan; Shaikh, Taha Gul; Waseem, Summaiyya; Qadir, Nashwa Abdul; Yousaf, Zohaib; Ullah, Irfan
title: Vaccine-induced thrombotic thrombocytopenia following coronavirus vaccine: A narrative review
date: 2021-10-30
journal: Ann Med Surg (Lond)
DOI: 10.1016/j.amsu.2021.102988
sha: d55614bb05e0020a70e1cd8e7fc9367b96cc9d6c
doc_id: 755885
cord_uid: c8c6xa05

The novel coronavirus pandemic has taken a toll on the global healthcare systems and economy. Safety precautions, along with vaccination, are the most effective preventive measures. The global vaccination program against COVID-19 has dramatically reduced the number of deaths and cases. However, the incidence of thrombotic events and thrombocytopenia post-COVID-19 vaccination known as vaccine-induced thrombotic thrombocytopenia has raised safety concerns. This has led to an element of vaccine hesitancy. The exact mechanism for vaccine-induced thrombotic thrombocytopenia is unknown. Although the incidence of thrombosis associated with COVID-19 vaccination is low, it still requires attention, especially in older people, smokers, and people with preexisting comorbidities. This study aims to review the pathophysiology, diagnosis, and management of vaccine-induced thrombotic thrombocytopenia, to provide a concise and comprehensive update.

The Severe Acute Respiratory Syndrome Coronavirus (SARS-CoV-2) cases were initially reported in Wuhan, China, towards the end of 2019. Following its extensive spread, the World Health Organization (WHO) declared COVID-19 a pandemic in March 2020. [1] To the date, April 16, approximately 207 million confirmed cases have been reported, and 4.3 million deaths [2] . Coordinated global efforts led to the development of COVID-19 vaccines, followed by emergency use authorization within nine months of the pandemic [3] . These vaccines are now widely available for public administration [4] . The vaccines are safe and effective in preventing severe infection, hospitalization, and death [5, 6] . To date, 4.4 billion vaccine doses have been administered [2] . The common adverse effects following COVID-19 vaccination are injection site pain and transient, self-limited systemic symptoms like headache, fever, myalgias, etc. [7] .

Recently, a more severe adverse effect, thrombocytopenia with or without thrombosis, has been reported following SARS-CoV-2 vaccination. Thrombocytopenia is a medical condition characterized by platelets lower than 150,000/microliter and is associated with a risk of bleeding and thrombosis [8] . Such reports have raised concerns over the safety profile and hesitancy towards the available vaccines [9] . The term "Vaccine-Induced Thrombotic Thrombocytopenia" describes post-vaccination thrombocytopenia cases. VITT is characterized by thrombosis at unusual sites and thrombocytopenia following vaccination [9] .

While VITT has been associated with both mRNA and viral vector vaccines, its prevalence is higher in viral vectored vaccines [7] . Following the incidence of 30 thromboembolism cases in March 2021, Oxford/AstraZeneca (AZD1222) was transiently suspended in numerous European countries [10] . Later the pharmacovigilance risk assessment committee (PRAC) of the European medical agency (EMA) reviewed all cases and declared thrombosis and thrombocytopenia as rare adverse effects of AZD1222. However, based on risk-benefit assessment, the vaccine was later declared safe for use [11] . Owing to a similar reason, in April 2021, Johnson & Johnson's Janssen (Ad26.CoV2.S) administration was also temporarily suspended [12] . Herein, we review the association between SARS-CoV-2 vaccines and VITT. This review evaluates the potential pathophysiology and clinical approach to diagnoses and management of VITT.

The work has been reported in line with the PRISMA 2020 criteria [13] . Two authors (SHA, SW) dependently conducted a thorough literature search over PubMed and Clinicaltrials.gov from inception till August 16, 2021, without any language restriction. To achieve comprehensive results, search string comprised of keywords, "SARS-CoV-2 Vaccine", "Coronavirus Vaccine," "Corona Vaccine," "COVID-19 Vaccine", "thrombotic thrombocytopenic," "Vaccine-Induced Thrombotic Thrombocytopenia," "VITT," "thrombocytopenia," "reduced platelet count," using BOOLEAN operators. Synonyms, related terms, and spelling variants were also engaged. All relevant case reports, case series, cohort studies, editorials, and correspondences were reviewed. Any discrepancies were resolved via discussion with a third reviewer (IU). The results of the literature search are shown in figure 1. Following studies selection, two independent authors (TGS, NAQ) extracted all the J o u r n a l P r e -p r o o f relevant data into a table comprising of author's name, patient's age, and sex, past medical history, presenting complaint, laboratory findings, radiological findings, treatment interventions, and outcome. Any discrepancies were resolved by discussion with a third reviewer (IU). All significant findings are summarized in table 1. 

The retrieved studies comprise data of 44 patients (32 females, 11 males, 1 not defined) with a mean age of 44.9 ± 14.3 years. The following figure (Figure 2 ) depicts the geographical distribution of the reported cases around the globe, with the majority of cases arising in Europe. Based on these and future reporting, we can predict the potential spatial spread, geographical locations that may be more susceptible than others and this may help us J o u r n a l P r e -p r o o f establish links between different genetic and environmental factors, predisposing an individual to such consequences of vaccines.

The exact pathophysiology behind VITT is unclear. As shown in Table 1 , most of the cases presented with thrombocytopenia, elevated D-dimer, and positive titers of IgG antibodies against platelet factor 4 (PF-4)[14 -22] . Based on these findings, this syndrome is closely related to heparin-induced thrombocytopenia (HIT), a medical condition characterized by thrombocytopenia, and the presence of antibodies against the Heparin-PF4 complex [23] .

HIT, an autoimmune reaction to heparin, involves the generation of IgG antibodies against the Heparin-PF4 complex. The Fc portion of these antibodies adheres to the complex, binds to the FcYRIIa receptors [24] , and initiates platelets activation via intracellular signaling involving spleen tyrosine kinase [25] . This results in the release of microparticles and a procoagulant state [26, 27] . Furthermore, clearance of activated and antibody-bound platelets by the reticuloendothelial system culminates in thrombocytopenia [28] . A prerequisite in the diagnosis of HIT includes a known recent exposure to heparin. A condition labeled "Autoimmune Heparin-Induced Thrombocytopenia (aHIT)" manifests with clinical and laboratory findings without any prior use of heparin [29] . Based on this resemblance, a comparison has been drawn between VITT and variants of aHIT [30] , and hence, we may assume that a similar mechanism follows post-vaccination. However, the mechanism behind the generation of these antibodies is yet to be elucidated.

In HIT, the electrostatic interaction between positively charged PF4 and negatively charged heparin culminates in the formation of the Heparin-PF4 complex [31] . This phenomenon has also been observed with other negatively charged molecules like numerous polyphosphates [32] , Polyvinyl phosphonate [33] , nucleic acids [34] , etc. According to Visentin et al. [33] , numerous negatively charged molecules, spaced about 0.5 nm apart along the molecular backbone and of sufficient length, can form complexes with PF4 while being detectable by the antibodies. Hence, components of vaccines can be expected to play a crucial role in the generation of PF4-polyanions complex and antibodies against them. Moreover, environmental factors and genetic predisposition can exacerbate clinical presentation. For example, specific genotypes encoding FcRIIA have been associated with an increased risk of thrombosis in individuals with anti-PF4-polyanion antibodies [24] .

Another postulated mechanism involves cross-reactivity of anti-SARS-CoV-2 spike protein antibodies that generates following SARS-CoV-2 vaccination with PF4. This may be attributable to molecular mimicry, a phenomenon whereby a certain degree of resemblance exists between the pathogens and the host's antigens [35] . Kanduc et al. [36] report massive homogeneity between the SARS-CoV-2 spike glycoprotein and human proteins, thus further strengthening this hypothesis. This structural resemblance can also explain the findings of thrombocytopenia [37] and anti-PF4 antibodies [38] in certain SARS-CoV-2 patients. However, the currently available literature suggests no evidence of cross-reactivity [38, 39] .

Zhang et al. [40] investigated the findings of thrombosis and thrombocytopenia in SARS-CoV-2 patients. They reported spike protein's ability to stimulate platelet activation and thrombus formation via the Mitogen-activated protein kinase (MAPK) pathway. Based on the findings [40] , the generation of spike protein following vaccination can also play a pivotal role in inducing thrombocytopenia and thrombosis via spike protein-ACE2 interaction-induced platelets activation. However, it remains unanswered if similar interactions can be observed post-vaccination with vector or mRNA vaccines. Moreover, some evidence [41] reveals potential interactions between adenovirus particles and circulating platelets leading to platelet activation and aggregation. The possibility of such interactions in the case of viral vector-based vaccines cannot be ruled out and requires further investigation. Furthermore, as shown in table 1, the findings of negative anti-PF4 antibodies in selective cases indicate involvement of a non-HIT like mechanism hence strengthening the above suggested hypothesis.

Future research should focus on potential interactions between spike proteins and platelets and the phenomenon of cross-reactivity. Another intriguing aspect of the higher prevalence of VITT among individuals vaccinated with viral vector-based vaccines needs to be investigated in the search for potential links. Development of thrombosis in selective individuals and incidence of rare site thrombosis like cerebral venous sinuses deserve equal attention for the exact pathophysiology to be elucidated. Lastly, the development of anti-PF4 antibodies only in certain VITT patients can also provide important clues in determining the pathogenesis.

Following the escalation in reported thrombocytopenia and thrombosis cases post COVID-19 vaccination, the American Society of Hematology (ASH) reviewed all the reported cases and laid specific ground rules to diagnose this novel presentation. As per the ASH [42] , cases meeting the following criteria can be identified as VITT: Individuals presenting with the complaints of severe headache, visual changes, abdominal pain, nausea, vomiting, back pain, shortness of breath, leg pain or swelling, petechiae, easy bruising, or bleeding, 4 to 42 days post-vaccination, must be evaluated critically for the condition mentioned above. Laboratory investigations, including CBC with platelet count, PF4 ELISA, d-dimer, fibrinogen, and imaging techniques for thrombosis, can play a crucial role in timely diagnosis and management. [42] Management Currently, numerous potential pharmacological therapies are being evaluated in the line of management for VITT. The outcomes range from being propitious to contraindicated or variable in different individuals. Briefed below are specific interventions being employed to overcome VITT.

The currently available evidence acknowledges IVIG as a potential treatment depicting remarkable success. Hence it is now incorporated into the treatment regimen. A potential explanation for this involves the Fcγ receptor blockade by the antibodies. The recommended dose in VITT is 1-2g/kg of the person's body weight. However, ideally, the administered IVIG should be the ones collected before the pandemic. The plausible explanation being vaccine response deterioration due to COVID-19 antibodies present in the donated IGs [43] .

There has been growing evidence of their efficacy in patients with VITT [44] . In some instances, preliminary trials to validate its effectiveness and progressive clinical worsening in some instances [45] have raised suspicions over its use regarding heparin. Therefore, the American society of hematology (ASH) suggests avoiding the use of heparin unless VITT has been ruled out or another condition diagnosed [42] The drug of choice is direct oral anticoagulants (dabigatran, apixaban, rivaroxaban, edoxaban, and fondaparinux) or parenteral direct thrombin inhibitors (e.g., bivalirudin and argatroban). The absolute contraindication following anti-coagulation therapy includes a high risk of bleeding. Hence strict clinical monitoring is crucial after initiating oral anticoagulants.

Most cases of VITT described steroids as a clinically effective treatment option. However, further data is needed to move past the anecdotal evidence. The above data and prediction are based on their successfully reported usage in our included cases and recently, by Schultz et al. [46] , where the combined IVIG and steroids were supported.

This therapy is only indicated in significant bleeding. Goel et al. [47] reported a five times increase in mortality of patients infused with platelets following thrombocytopenia. In our included studies, eight reportedly administered platelet infusion. Following Goel et al. [47, 48] , only two patients survived [49] .

Plasma exchange was used in three cases. Two out of the three patients survived [50] [51] . Relevant details by Garnier et al. were unavailable [14] . Plasma exchange is used in refractory VITT [52] . Clinically, there is insufficient data to evaluate whether plasma exchange can be administered safely in VITT. Plasma exchange is not a standard treatment option in HIT [42] . Extrapolating this to VITT, we may assume similar effects on patients with VITT. However, more data is required to draw any conclusion.

Aspirin or other anti-platelets are currently contra-indicated in VITT due to increased risk of bleeding. Smith et al. [53] suggested a possible prophylactic role of antiplatelets in VITT. This highlights the need for more work in this area.

Rituximab is not recommended currently due to its longer response time (6-8 weeks) [42] . Moreover, this drug's mechanism of action can be explained via its downregulation of CD-20 B-cells. This can potentially lead to the inactivation of antibodies against COVID-19, hence rendering the vaccine administration useless.

The following regimen is per the American Society of Hematology (ASH) [42] , International Society on Thrombosis and Haemostasis (ISTH) [54] , and National Institute for Health and Care Excellence (NICE) in the United Kingdom:

1. Start IVIG.

2. The ISTH guidelines recommend administering steroids if a patient's platelet count is less than 50 x 109/L. 3. Platelet infusion and plasma exchange should not be considered initially. 4. Based on their history and previous clinical profile, patients shall be started an anticoagulant (non-heparin). Vitamin K antagonists should be avoided while the platelet count is low. Moreover, direct thrombin inhibitors should be avoided in pregnant women. DOACs and fondaparinux are suitable for noncritically ill patients. 5. For patients having less than 50 ×103/μL and severe risk of bleeding, IV direct thrombin inhibitors can be used. This will lead to a shorter half-life and rapid action. 6. Fibrinogen levels should be strictly monitored and kept in range (>1.5 g/L.) 7. If platelet count remains less than 30 x 109/L despite intravenous immunoglobulin and steroid treatment or fibrinogen level is less than 1 g/L, plasma exchange can be considered after an opinion with hematologists.

VITT is a rare adverse effect of SARS-CoV-2 vaccination, and the benefits of COVID-19 vaccines continue to outweigh the rare side effects. However, while its incidence is low, there is undoubted an overwhelming need to discern the precise pathophysiology behind this syndrome to establish proper management protocols. Questions like why certain coronavirus vaccines carry a higher risk than others, why specific individuals develop thrombosis while others don't, higher prevalence in a particular gender and age group, and the impact of different interventions in such patients need to be investigated before a clear conclusion can be drawn. Lastly, future studies must take into consideration both pre-and post-vaccination investigations to discern the role of any underlying condition.

J o u r n a l P r e -p r o o f 

Covid-19: WHO declares pandemic because of "alarming levels" of spread, severity, and inaction

Myanmar: WHO Coronavirus Disease (COVID-19) Dashboard With Vaccination Data | WHO Coronavirus (COVID-19) Dashboard With Vaccination Data

FDA Takes Key Action in Fight Against COVID-19 By Issuing Emergency Use Authorization for First COVID-19 Vaccine | FDA

Maintaining Safety with SARS-CoV-2 Vaccines

Vaccine efficacy, effectiveness and protection

Planning and provision of ECMO services for severe ARDS during the COVID-19 pandemic and other outbreaks of emerging infectious diseases

Safety of COVID-19 vaccines administered in the EU: Should we be concerned?

Cerebral venous sinus thrombosis associated with vaccine-induced thrombotic thrombocytopenia

Thrombocytopenia and Intracranial Venous Sinus Thrombosis after "COVID-19 Vaccine AstraZeneca

A case of thrombocytopenia and multiple thromboses after vaccination with ChAdOx1 nCoV-19 against SARS-CoV-2

Heparin-induced thrombocytopenia (HIT): Review of incidence, diagnosis, and management

Risk factors for heparin-induced thrombocytopenia: Focus on Fcγ receptors

PRT-060318, a novel Syk inhibitor, prevents heparin-induced thrombocytopenia and thrombosis in a transgenic mouse model

Platelet factor 4-containing immune complexes induce platelet activation followed by calpaindependent platelet death

Activated platelet-derived and leukocyte-derived circulating microparticles and the risk of thrombosis in heparin-induced thrombocytopenia: a role for PF4-bearing microparticles?

Journal of thrombosis and haemostasis

Autoimmune heparin-induced thrombocytopenia

Heparin-induced thrombocytopenia

Determinants of PF4/heparin immunogenicity

Polyphosphate/platelet factor 4 complexes can mediate heparin-independent platelet activation in heparininduced thrombocytopenia

Heparin is not required for detection of antibodies associated with heparin-induced thrombocytopenia/thrombosis

Complex formation with nucleic acids and aptamers alters the antigenic properties of platelet factor 4

Molecular mimicry: a critical look at exemplary instances in human diseases

Molecular mimicry between SARS-CoV-2 spike glycoprotein and mammalian proteomes: implications for the vaccine

Immune Thrombocytopenic Purpura in a Patient with Covid-19

Antibody-mediated procoagulant platelets in SARS-CoV-2-vaccination associated immune thrombotic thrombocytopenia

Anti-SARS-CoV-2 spike protein and anti-platelet factor 4 antibody responses induced by COVID-19 disease and ChAdOx1 nCov-19 vaccination

SARS-CoV-2 binds platelet ACE2 to enhance thrombosis in COVID-19

Adenovirus type 3 induces platelet activation in vitro

COVID-19 Vaccines: What Cardiovascular Clinicians Need to Know -American College of Cardiology

Untangling the Intricacies of Infection, Thrombosis, Vaccination, and Antiphospholipid Antibodies for COVID-19

Vaccine-Induced Immune Thrombotic Thrombocytopenia (VITT): Targeting Pathomechanisms with Bruton Tyrosine Kinase Inhibitors

COVID-19: Vaccine-induced immune thrombotic thrombocytopenia (VITT) -UpToDate

Thrombosis and Thrombocytopenia after ChAdOx1 nCoV-19 Vaccination

Platelet transfusions in platelet consumptive disorders are associated with arterial thrombosis and in-hospital mortality

Immune thrombocytopenia in a 22-year-old post Covid-19 vaccine

Thrombosis and thrombocytopaenia after ChAdOx1 nCoV-19 vaccination: a single UK centre experience

COVID-19 vaccine induced prothrombotic immune thrombocytopenia

Acquired thrombotic thrombocytopenic purpura after first vaccination dose of BNT162b2 mRNA COVID-19 vaccine

Therapeutic plasma exchange in clinical practice: long-term single centre experience

Rituximab (monoclonal anti-CD20 antibody): mechanisms of action and resistance

The ISTH Releases Interim Guidance on Vaccine-Induced Immune Thrombotic Thrombocytopenia (VITT) -International Society on Thrombosis and Haemostasis, Inc

A 59-Year-Old Woman with Extensive Deep Vein Thrombosis and Pulmonary Thromboembolism 7 Days Following a First Dose of the Pfizer-BioNTech BNT162b2 mRNA

Thrombotic Thrombocytopenia after Ad26.COV2.S Vaccination

Management of a patient with a rare congenital limb malformation syndrome after SARS-CoV-2 vaccine-induced thrombosis and thrombocytopenia (VITT)

Vaccine Induced Immune Thrombotic Thrombocytopenia Causing a Severe Form of Cerebral Venous Thrombosis With High Fatality Rate: A Case Series

Neurosurgical Considerations Regarding Decompressive Craniectomy for Intracerebral Hemorrhage after SARS-CoV-2-Vaccination in Vaccine Induced Thrombotic Thrombocytopenia-VITT

Cerebral Venous Thrombosis after BNT162b2 mRNA SARS-CoV-2 vaccine

SARS-CoV-2 vaccine-induced immune thrombotic thrombocytopenia treated with immunoglobulin and argatroban

Pulmonary embolism, transient ischaemic attack and thrombocytopenia after the Johnson & Johnson COVID-19 vaccine

A Rare Case of Cerebral Venous Thrombosis and Disseminated Intravascular Coagulation Temporally Associated to the COVID-19 Vaccine Administration

The authors declare that there is no conflict of interests

Not commissioned, externally peer-reviewed

The following information is required for submission. Please note that failure to respond to these questions/statements will mean your submission will be returned. If you have nothing to declare in any of these categories then this should be stated.

All authors must disclose any financial and personal relationships with other people or organisations that could inappropriately influence (bias) their work. Examples of potential conflicts of interest include employment, consultancies, stock ownership, honoraria, paid expert testimony, patent applications/registrations, and grants or other funding.

Please state any sources of funding for your research All sources of funding should be declared as an acknowledgement at the end of the text. Authors should declare the role of study sponsors, if any, in the collection, analysis and interpretation of data; in the writing of the manuscript; and in the decision to submit the manuscript for publication. If the study sponsors had no such involvement, the authors should so state.

Research studies involving patients require ethical approval. Please state whether approval has been given, name the relevant ethics committee and the state the reference number for their judgement. NA J o u r n a l P r e -p r o o f Consent Studies on patients or volunteers require ethics committee approval and fully informed written consent which should be documented in the paper.Authors must obtain written and signed consent to publish a case report from the patient (or, where applicable, the patient's guardian or next of kin) prior to submission. We ask Authors to confirm as part of the submission process that such consent has been obtained, and the manuscript must include a statement to this effect in a consent section at the end of the manuscript, as follows: "Written informed consent was obtained from the patient for publication of this case report and accompanying images. A copy of the written consent is available for review by the Editor-in-Chief of this journal on request".Patients have a right to privacy. Patients' and volunteers' names, initials, or hospital numbers should not be used. Images of patients or volunteers should not be used unless the information is essential for scientific purposes and explicit permission has been given as part of the consent. If such consent is made subject to any conditions, the Editor in Chief must be made aware of all such conditions. Even where consent has been given, identifying details should be omitted if they are not essential. If identifying characteristics are altered to protect anonymity, such as in genetic pedigrees, authors should provide assurance that alterations do not distort scientific meaning and editors should so note.

Please specify the contribution of each author to the paper, e.g. study concept or design, data collection, data analysis or interpretation, writing the paper, others, who have contributed in other ways should be listed as contributors. SHA, IU: Study concept or design SHA, SW, TGS, NAQ and IU: Data collection, data analysis or interpretation, writing the paper ZY: Critical revision of the article J o u r n a l P r e -p r o o f

In accordance with the Declaration of Helsinki 2013, all research involving human participants has to be registered in a publicly accessible database. Please enter the name of the registry and the unique identifying number (UIN) of your study.You can register any type of research at http://www.researchregistry.com to obtain your UIN if you have not already registered. This is mandatory for human studies only. Trials and certain observational research can also be registered elsewhere such as: ClinicalTrials.gov or ISRCTN or numerous other registries.

Name of the registry: NA

Unique Identifying number or registration ID: NA

Hyperlink to your specific registration (must be publicly accessible and will be checked): NA

The Guarantor is the one or more people who accept full responsibility for the work and/or the conduct of the study, had access to the data, and controlled the decision to publish